Shire Continues to Deliver Excellent Growth From Cor...(1.5 23.0 Interest expense ...),Health

Date:10/30/2009

1.5 23.0 Interest expense (9.4) (92.9) (30.6) (127.0) Other income/(expenses), net 7.0 (52.0) 61.9 (38.6) Total other (expense)/income, net (2.2) (141.1) 32.8 (142.6) Income/(loss) from continuing operations before income taxes and equity in earnings of equity method investees 89.6 (18.2) 385.2 76.0 Income taxes (30.6) (18.7) (56.7) (63.0) Equity in earnings of equity method investees, net of taxes 0.6 1.6 1.0 1.3 Income/(loss) from continuing operations, net of tax 59.6 (35.3) 329.5 14.3 Loss from discontinued operations (net of income tax expense of $nil in all periods) - (0.9) (12.4) (0.9) Net income/(loss) 59.6 (36.2) 317.1 13.4 Add: Net loss attributable to noncontrolling interest in subsidiaries - 1.3 0.2 1.3 Net income/(loss) attributable to Shire plc 59.6 (34.9) 317.3 14.7 (1) Cost of product sales includes amortization of intangible assets relating to favorable manufacturing contracts of $0.4 million for the three months to September 30, 2009 (2008: $0.4 million) and $1.3 million for the nine months to September 30, 2009 (2008: $1.3 million). Selling, general and administrative costs include amortization and impairment charges of intangible assets relating to intellectual property rights acquired of $34.8 million for the three months to September 30, 2009 (2008: $29.7 million) and $101.6 million for the nine months to September 30, 2009 (2008: $181.9 million). (2) Promotional costs totaling $6
'/>"/>

SOURCE Shire Plc Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33
Related medicine technology :

1. Shire Strives to Increase Adherence Among Chronic Kidney Disease Stage 5 Patients
2. Shire Enhances its Orphan Drug Pipeline With the Acquisition of a New Clinical Candidate for Metachromatic Leukodystrophy
3. Shire to Present Additional Scientific Data on ADHD Treatment Portfolio at American Psychiatric Association Annual Meeting
4. Shires Investigational Nonstimulant ADHD Treatment INTUNIV(TM) (Guanfacine Extended Release) Demonstrated Significant Efficacy in Reducing ADHD Symptoms at All Measured Time Points Up to 24 Hours Postdose
5. Shire Announces Approval of ELAPRASE(R) (idursulfase) in Brazil
6. Shire to add New Orphan Drug to its HGT Portfolio - EU Launch Imminent
7. Shire Withdraws European Application for DAYTRANA(TM) (Methylphenidate Transdermal System)
8. Shire Announces Study Results of the Effects of INTUNIV(TM) (Guanfacine) Extended Release on Secondary Measures in Children with ADHD and Oppositional Symptoms
9. Shire Presented Results of a New Database Analysis on Lialda(R) (Mesalamine) and Other 5-ASAs for Ulcerative Colitis at Digestive Disease Week
10. Shire has Filed a Treatment Protocol for Velaglucerase Alfa for Gaucher Disease
11. Shire Receives Fast Track Designation for velaglucerase alfa for Gaucher Disease